Industry Analysts Just Made A Captivating Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts [Yahoo! Finance]
Mersana Therapeutics, Inc. (MRSN)
Last mersana therapeutics, inc. earnings: 2/28 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
mersana.com/about-mersana
Company Research
Source: Yahoo! Finance
The consensus estimated revenue numbers rose, with their view now clearly much more bullish on the company's business prospects. Following the latest upgrade, the current consensus, from the ten analysts covering Mersana Therapeutics, is for revenues of US$25m in 2025, which would reflect a disturbing 37% reduction in Mersana Therapeutics' sales over the past 12 months. Per-share losses are expected to explode, reaching US$0.71 per share. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$23m and losses of US$0.71 per share in 2025. So there's definitely been a change in sentiment in this update, with the analysts upgrading this year's revenue estimates, while at the same time holding losses per share steady. Check out our latest analysis for Mersana Therapeutics NasdaqGS:MRSN Earnings and Revenue Growth March 5th 2025 The consensus price target fell 13% to US$4.71 asthe analysts signal that ongoing losses are likely to weigh on the stock price
Show less
Read more
Impact Snapshot
Event Time:
MRSN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRSN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRSN alerts
High impacting Mersana Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MRSN
News
- Shareholder Alert: The Ademi Firm continues to investigate whether Mersana Therapeutics Inc. is obtaining a Fair Price for its Public ShareholdersPR Newswire
- Why Analysts See Mersana's Story Shifting To Deal And CVR Outcomes After $1B Buyout [Yahoo! Finance]Yahoo! Finance
- Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSNPR Newswire
- BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mersana Therapeutics, Inc. (Nasdaq - MRSN), Cidara Therapeutics, Inc. (Nasdaq - CDTX), Cadence Bank (NYSE – CADE)GlobeNewswire
- Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their RightsGlobeNewswire
MRSN
Earnings
- 11/14/25 - Miss
MRSN
Sec Filings
- 12/5/25 - Form SC
- 12/5/25 - Form SC
- 12/4/25 - Form SC
- MRSN's page on the SEC website